Advertisement

Topics

"Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)" Drugs and Medication Database

05:42 EST 17th February 2019 | BioPortfolio

Here are the most relevant "Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)" Drugs and Medications that we have found in our database.

More Information about "Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)" on BioPortfolio

We have published hundreds of Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) news stories on BioPortfolio along with dozens of Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) Clinical Trials and PubMed Articles about Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) Companies in our database. You can also find out about relevant Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) Drugs and Medications on this site too.

Showing "Evaluation Cardiovascular Outcomes Patients With Type Diabetes After" Drugs and Medications, all 3

Possibly Relevant

Nesina [takeda pharmaceuticals america, inc.]

These highlights do not include all the information needed to use NESINA safely and effectively. See full prescribing information for NESINA. NESINA (alogliptin) tablets, for oral use Initial U.S. Approval: 2013

Alogliptin [perrigo new york inc]

These highlights do not include all the information needed to use ALOGLIPTIN TABLETS safely and effectively. See full prescribing information for ALOGLIPTIN TABLETS. Alogliptin Tablets, for oral use Initial U.S. Approval: 2013

Metformin hydrochloride [blenheim pharmacal, inc.]

METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, USP



Advertisement
Quick Search
Advertisement
Advertisement